Advances in cellular and humoral immunotherapy – implications for the treatment of poor risk childhood, adolescent, and young adult B-cell non-Hodgkin lymphoma

Yaya Chu, Aliza Gardenswartz, Amanda M. Termuhlen, Mitchell S. Cairo

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations

Abstract

Patients with relapsed, refractory or advanced stage B non-Hodgkin lymphoma (NHL) continue to have a dismal prognosis. This review summarises current and novel cellular and immunotherapy for these high-risk populations, including haematopoietic stem cell transplant, bispecific antibodies, viral-derived cytotoxic T cells, chimeric antigen receptor (CAR) T cells, and natural killer (NK) cell therapy, as discussed at the 6th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma on September 26th–29th 2018 in Rotterdam, the Netherlands, and explores the future of NK/CAR NK therapies.

Original languageEnglish (US)
Pages (from-to)1055-1070
Number of pages16
JournalBritish journal of haematology
Volume185
Issue number6
DOIs
StatePublished - Jun 2019

Bibliographical note

Funding Information:
Supported in part by grants from Pediatric Cancer Research Foundation (MSC), St. Baldrick’s Foundation (MSC), New York Medical College School of Medicine Translational Science Institute Children Health Translational Research Award (YC), National Cancer Institute (MSC) (1R13CA232383-01) and National Heart, Lung and Blood Institute (MSC) (1R13CA232383-01).

Keywords

  • B-cell non-Hodgkin lymphoma
  • IL-15 superagonist
  • cellular immunotherapy
  • chimeric antigen receptor
  • stem cell transplantation

Fingerprint Dive into the research topics of 'Advances in cellular and humoral immunotherapy – implications for the treatment of poor risk childhood, adolescent, and young adult B-cell non-Hodgkin lymphoma'. Together they form a unique fingerprint.

Cite this